Pyrrolo[1,2-b]pyridazine compounds and their uses

Details Pyrrolo[1,2-b]pyridazine compounds and their uses Pyrrolo[1,2-b]pyridazine compounds and their uses

2006-07-11

2006-07-11

Habte, Kahsay (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S235000

Reexamination Certificate

active

07074791

ABSTRACT:
Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I):including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R1and R2are independently selected from H, Me or OMe.

REFERENCES:
patent: 6043260 (2000-03-01), Chen et al.
patent: 6589947 (2003-07-01), Hamanaka et al.
patent: 2001/0007867 (2001-07-01), Chen
patent: 2002/0151713 (2002-10-01), Chen
patent: 1085021 (1999-05-01), None
patent: 1097709 (2000-10-01), None
patent: 1085021 (2001-03-01), None
patent: 9808847 (1998-03-01), None
patent: WO 9808847 (1998-03-01), None
patent: 0272101 (2002-09-01), None
patent: 0272202 (2002-09-01), None
patent: WO 2072101 (2002-09-01), None
patent: WO 2072202 (2002-09-01), None
Chalmers (TiPS vol. 17 , pp. 166-172 Apr. 1996).
Zorrilla et al. Expert Opin. Investig. Drugs (2004) 13(7).
Kehne et al. Current Drug Targets -CNS & Neurological Disorders 2002, vol. 1, No. 5 pp. 467-493.
J. Rivier et al.,Proc. Natl. Acad. Sci(USA) 80:4851 (1983).
W. Vale et al.,Science213:1394 (1981).
W. Vale et al.,Rec. Prog. Horin. Res. 39:245 (1983).
G.F. Koob,Persp. Behav. Med. 2:39 (1985).
E.B. De Souza et al.,J. Neurosci. 5:3189 (1985).
Physiological Reviews69:1 (1989).
J.E. Morley,Life Sci. 41:527 (1987).
E.B. De Souze,Hosp. Practice23:59 (1988).
C.B. Nemeroff et al.,Science226:1342 (1984).
C.M. Banki et al.,Am. J. Psychiatry144:873 (1987).
R.D. France et al.,Biol. Psychiatry23:86 (1988).
M. Arato et al.,Biol. Psychiatry25:355 (1989).
C.B. Memeroff et al.,Arch. Gen. Psychiatry45:577 (1988).
P.W. Gold et al.,Am. J. Psychiatry141:619 (1984).
F. Holsboer et al.,Psychoneuroendocrinology9:147 (1984).
P.W. Gold et al.,New Engl. J. Med. 314:1129 (1986).
R.M. Sapolsky,Arch. Gen. Psychiatry46:1047 (1989).
Grigoriadis et al.,Neuropsychopharmacology2:53 (1989).
The Merck Manual of Diagnosis and Therapy, 16thedition (1992).
D.R. Britton et al.,Life Sci. 31:363 (1982).
C.W. Berridge and A.J. Dunn,Regul. Peptides16:83 (1986).
C.W. Berridge and A.J. Dunn,Horm. Behav. 21:393 (1987).
Brain Research Reviews15:71 (1990).
G.F. Koob and K.T. Britton, In:Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E.B. De Souza and C.B. Nemeroff eds., CRC Press p. 221 (1990).
K.T. Britton et al.,Psychopharmacology86:170 (1985).
K.T. Britton et al.,Psychopharmacology94:306 (1988).
N.R. Swerdlow et al.,Psychopharmacology88:147 (1986).
E.L. Webster et al.,J. Rheumatol29(6):1252 (2002.
E.P. Murphy et al.,Arthritis Rheum44(4):782 (2001).
K.E. Gabry et al.,Molecular Psychiatry 7(5): 474 (2002).
C.C. Zouboulis et al.,Proc. Natl. Acad. Sci. 99: 7148 (2002).
K. Kaneko et al.,Exp Dermatol12(1): 47 (2003).
Ahman, J. and Buchwald, S. L.Tetrahydron Lett. 1997, 38, 6363.
Wolfe, J. P. and Buchwald, S. L. J. Org.Chem. 2000, 65, 1144.
T. Higuchi and V. Stella, “Prodrugs as Novel Delivery Systems”, vol. 14 of the A.C.S. Symposium Series; Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, (1987).
Notari, R. E., “Theory and Practice of Prodrug Kinetics,” Methods in Enzymology, 112:309-323 (1985).
Bodor, N., “Novel Approaches in Prodrug Design,” Drugs of the Future, 6(3):165-182 (1981).
Bundgaard, H., “Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemical Entities,” in Design of Prodrugs (H. Bundgaard, ed.), Elsevier, N.Y. (1985).
Burger's Medicinal Chemistry and Drug Chemistry, Fifth Ed., vol. 1, pp. 172-178, 949-982 (1995).
DeSouza et al. J.Neuroscience7:88, 1987.
Battaglia et al.Synapse1:572, 1987.

Affiliated with

Also associated with

Rating

Pyrrolo[1,2-b]pyridazine compounds and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolo[1,2-b]pyridazine compounds and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo[1,2-b]pyridazine compounds and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3602162